GLOBAL BLOOD THERAPEUTICS IN's ticker is GBT and the CUSIP is 37890U108. A total of 196 filers reported holding GLOBAL BLOOD THERAPEUTICS IN in Q4 2018. The put-call ratio across all filers is 0.35 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $6,594,000 | -51.2% | 124,583 | -62.2% | 0.01% | -57.9% |
Q4 2018 | $13,520,000 | -45.3% | 329,344 | -49.4% | 0.02% | +26.7% |
Q3 2018 | $24,710,000 | +69.0% | 650,264 | +101.0% | 0.02% | -16.7% |
Q2 2018 | $14,624,000 | +0.7% | 323,544 | +7.6% | 0.02% | -5.3% |
Q1 2018 | $14,528,000 | +28.1% | 300,779 | +4.3% | 0.02% | +26.7% |
Q4 2017 | $11,343,000 | +33.2% | 288,254 | +5.1% | 0.02% | +25.0% |
Q3 2017 | $8,515,000 | +21.1% | 274,250 | +6.7% | 0.01% | +20.0% |
Q2 2017 | $7,032,000 | +22.2% | 257,127 | +64.6% | 0.01% | +25.0% |
Q1 2017 | $5,756,000 | +1241.7% | 156,195 | +426.2% | 0.01% | +700.0% |
Q4 2016 | $429,000 | -25.1% | 29,682 | +19.3% | 0.00% | 0.0% |
Q3 2016 | $573,000 | +55.3% | 24,870 | +11.7% | 0.00% | 0.0% |
Q2 2016 | $369,000 | +132.1% | 22,272 | +122.2% | 0.00% | – |
Q1 2016 | $159,000 | -50.9% | 10,025 | 0.0% | 0.00% | -100.0% |
Q4 2015 | $324,000 | +9.8% | 10,025 | +43.5% | 0.00% | 0.0% |
Q3 2015 | $295,000 | – | 6,986 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Alerce Investment Management, L.P. | 356,270 | $24,262,000 | 23.36% |
Twin Securities, Inc. | 376,669 | $25,651,000 | 11.94% |
Paradigm Biocapital Advisors LP | 1,175,879 | $80,077,000 | 10.68% |
Chicago Capital Management, LLC | 246,246 | $16,769,000 | 9.12% |
HARVEST MANAGEMENT LLC | 141,500 | $9,636,000 | 7.78% |
Fernwood Investment Management, LLC | 174,724 | $11,899,000 | 5.02% |
ArchPoint Investors | 168,725 | $11,490,000 | 4.69% |
HAVENS ADVISORS LLC | 46,000 | $3,133,000 | 4.69% |
Perceptive Advisors | 2,322,247 | $158,145,000 | 4.59% |
Crabel Capital Management, LLC | 112,680 | $7,674,000 | 4.48% |